You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
爾康製藥(300267.SZ):磷酸哌嗪”、“雙嘧達莫”及“磷酸苯丙哌林”原料藥通過CDE審批
格隆匯 04-07 17:45

格隆匯4月7日丨爾康製藥(300267.SZ)公佈,近日,公司從國家藥品監督管理局藥品審評中心(CDE)“原料藥、藥用輔料和藥包材登記信息公示”平台查詢獲悉,全資子公司湖南湘易康製藥有限公司(“湘易康”)提交的“磷酸哌嗪”、“雙嘧達莫”、“磷酸苯丙哌林”原料藥(受理號:CYHT1600561、CYHT1600562、CYHT1600546)通過了CDE審批。

磷酸哌嗪為驅腸蟲藥,用於蛔蟲和蟯蟲的感染;雙嘧達莫為抗血小板聚集藥、冠狀動脈擴張藥,主要用於缺血性心臟病及中風;磷酸苯丙哌林為非麻醉性鎮咳藥,用於刺激性乾咳,對急、慢性支氣管炎及各種原因引起的咳嗽均可應用。

磷酸哌嗪”、“雙嘧達莫”、“磷酸苯丙哌林”原料藥通過CDE審批,有利於公司加快原料藥產業佈局,進一步豐富公司原料藥品種,完善原料藥產品結構,為公司構建“原輔料+製劑一體化”商業生態提供更多支持。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account